Wilson Disease Market Size To Hit US$ 422.0 Million By 2033
According to IMARC Group’s latest report, titled “Wilson Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2023-2033”, the 7 major wilson disease markets reached a value of US$ 308.3 Million in 2022. Looking forward, IMARC Group expects the 7MM to reach US$ 422.0 Million by 2033, exhibiting a growth rate (CAGR) of 2.88% during 2023-2033. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the market in any form.
Request for a Free Sample Copy of this Report:
https://www.imarcgroup.com/wilson-disease-market/requestsample
Industry Definition and Application:
Wilson disease refers to a rare genetic disorder in which copper accumulates throughout the body, particularly in the liver, brain, and eyes. It is caused by a mutation in the ATP7B gene, which is responsible for regulating the body's copper metabolism. The symptoms of this condition include lack of appetite, abdominal pain, yellowish whites of the eyes, fluid buildup in the legs or abdomen, fatigue, difficulty with speech, swallowing, or physical coordination, etc. Some patients may also suffer from psychiatric problems like depression and anxiety. The diagnosis of Wilson disease involves a combination of medical history, eye examination, genetic testing, and blood tests.
What are the growth prospects and trends in the industry?
The increasing instances of autosomal recessive
disorder, leading to gene variations and chromosomal abnormalities, are
primarily driving the Wilson disease market. Moreover, the escalating
utilization of copper chelation therapy with trientine and penicillamine to
lower the levels of copper in the blood and prevent further tissue and organ
damage is also contributing to the market growth. In addition to this, various
healthcare companies are increasingly investing in R&D activities to
develop effective metal toxicity medications with higher bioavailability, which
is acting as a substantial growth-inducing factor. Moreover, the rising need
for zinc acetate in maintenance therapy, which can limit the absorption of
copper into the bloodstream from food, thereby preventing excessive copper
buildup, is further offering lucrative growth opportunities to the market.
Besides this, the ongoing developments in gene therapy, such as the utilization
of adeno-associated vectors, which can transduce both quiescent and replicating
cell populations, are anticipated to propel the Wilson disease market in the
coming years.
Countries Covered:
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the wilson disease market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the wilson disease market
- Reimbursement scenario in the market
- In-market and pipeline drugs
This report also provides a detailed analysis of the wilson disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug overview
- Mechanism of action
- Regulatory status
- Clinical trial results
- Drug uptake and market performance
Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=7597&flag=C
Competitive Landscape With Key Players:
The competitive landscape of the epidermolysis bullosa market has been studied in the report with the detailed profiles of the key players operating in the market.
Key Highlights of the Report:
- Market Performance (2017-2022)
- Market Outlook (2023-2033)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.
Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: sales@imarcgroup.com
Phone: +1-631-791-1145
Address: 134 N 4th St
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com/
